DMRA

DMRA is in a Stage 2 advance within a secular uptrend, having broken out of consolidation and sustaining higher highs and lows. Price is currently extended above rising EMAs with extreme overbought readings, suggesting patience rather than chasing strength. Execution should be deferred, with entries targeted on shallow pullbacks into the rising EMA support zone or the prior resistance-turned-support area.

• ↑Post-Russell inclusion, stock rose 6.2%, boosting liquidity and visibility
• ↑Weekly gains of 11.7% highlight growing investor interest in oncology pipeline
• ↓Negative earnings yield and poor profitability underscore cash burn concerns